Introduction
Chromosomal translocations are a frequent feature of leukemias. Chromosome breakpoints often involve nuclear proteins, mainly transcription factors, and lead to the formation of fusion proteins where the regulatory and coding regions of a variety of transcription factor genes are rearranged. The resultant fusion protein products can interfere with the regulatory pathway(s) that controls the growth, differentiation and survival of normal blood cell progenitors/precursors. 1 There is also increasing evidence that these fusion proteins play a key role in the development of specific forms of leukemia and their formation must be considered as a key pathogenetic event. promyelocytic leukemia (PML) and retinoic acid receptor ␣ (RAR␣) genes. 2, 3 The PML breakpoints in APL can occur in three different sites: intron 6 (bcr 1 or long form), exon 6 (bcr 2 or variable form), and intron 3 (bcr 3 or short form). The most frequent sites are bcr 1 and bcr 3, whereas bcr 2 involvement is observed in only 8% to 10% of cases. 3 The result of the translocation is the generation of a novel PML/RAR␣ fusion protein that is thought to play a key role in the pathogenesis of APL, possibly interfering with the endogenous signaling pathways of both PML and RAR␣. [4] [5] [6] [7] [8] Recent studies indicate that PML/RAR␣ mediates leukemogenesis through aberrant chromatin acetylation. [9] [10] [11] The molecular mechanisms through which PML/RAR␣ interferes with cellular differentiation have been partially clarified; however, the cellular mechanisms which lead to a block of cell maturation at the level of promyelocytes remains largely unknown. In this context, studies on hematopoietic colonies derived from the blood of APL patients showed that the fusion transcript was observed in both BFU-E and CFU-GM. 12 The PML/RAR␣ transcript was detected only in the compartment of more mature CD34 + /CD38 + progenitors. 13 These observations suggest that APL develops from the immortalization and neoplastic transformation of a more differentiated cell type than the pluripotent progenitor and/or stem cell compartments implicated in other leukemia subtypes. 14 Transgenic mice expressing PML/RAR␣ offer an important and useful model for exploring the pathogenesis of APL, 15, 16 but have intrinsic limitations to investigate the cellular origin of the disease (reviewed in Ref. 17) .
Several recent studies carried out in vitro and in vivo have clearly shown that the large majority of APL cells undergoes granulocytic maturation following all-trans retinoic acid (ATRA) treatment. 18, 19 Although the ATRA-induced differentiation of APL cells is accompanied by significant induction of membrane antigens typically observed during granulomonocytic maturation (ie increase in the expression of ␤2 integrins (CD11a, CD11b, CD11c), selectin ligands (CD15 and CD15s), adhesion molecules (CD54) and tyrosine phosphatase isoforms (CD45RA and CD45RO)), 20 several findings indicate that ATRA is incapable of inducing complete morphological maturation of APL cells; in fact: (1) after ATRA induction the expression level of several differentiation markers is lower than that observed in normal neutrophils; 20 (2) fresh APL cells 21 as well as APL cell lines 22, 23 do not express secondary granules, after induction with ATRA.
Previous studies performed on a PML/RAR␣ + positive cell line, NB4, have shown that these cells under appropriate culture conditions could be induced to differentiate towards monocytes, thus suggesting the bipotential granulo-monocytic nature of APL blasts. 24, 25 To provide further insights into the cellular origin of APL and ATRA-induced differentiation pattern, we have investigated the expression of c-fms in freshly isolated APL cells and their ability to differentiate along both the granulocytic and 99 monocytic lineages. In normal hematopoietic cells the expression of c-fms is restricted to the monocytic lineage 26 and, thus, this receptor, in addition to playing an important role in the control of monocytic differentiation, can also be considered a specific marker of cells pertaining to the monocytic pathway. Our results show that c-fms is constitutively and constantly expressed in all cases of APL and its expression is further potentiated following induction with ATRA. A variable proportion of cells exhibit monocytic morphology and cell surface phenotype of monocytic cells following ATRA induction; the proportion of monocytic cells was consistently increased when the APL cells were incubated with ATRA combined with hematopoietic growth factors (HGFs) (ie IL-3+GM-CSF+M-CSF).
Materials and methods

Cells
Fresh leukemic blasts from 16 APL patients, obtained after informed consent, were isolated from either bone marrow or peripheral blood by Ficoll-Hypaque density centrifugation and immediately processed. Fourteen of these 16 cases were newly diagnosed APL patients classified as M3 by morphological criteria according to the French-American-British (FAB) classification and presented more than 80% infiltrating blasts. One case was an ATRA-resistant relapsing patient; in this patient (No. 10 in Table 1 
Differentiation assay
APL cells were grown in the above medium in the absence of additives (control) or in the presence of ATRA (1 × 10 −6 M; Sigma, St Louis, MO, USA) added alone or in combination with hematopoietic growth factors (HGFs): recombinant human (rh) M-CSF (R&D Systems, 6 × 10 7 units/mg) rh IL-3 and rh GM-CSF (2 × 10 6 U/mg and 2 × 10 8 U/mg, respectively) were obtained from the Genetics Institute (Cambridge, MA, USA); rh G-CSF (1 × 10 8 U/mg) was purchased from R&D Systems (Minneapolis, MN, USA).
In some experiments NB4 cells were treated for 4 days with either 1 M ATRA alone or in combination with M-CSF (10 ng/ml) or 250 ng/ml 1␣250H-Vitamin D3 (Roche, Basel, Switzerland) or 20 × 10 −9 M 12-O-tetradeconoylphorbol-13-acetate (TPA; Sigma, St Louis, MO, USA) or both agents together.
After different days of in vitro incubation, cells were harvested and assayed for cell vitality (by the trypan blue exclusion test) and cell differentiation. Cell differentiation was assessed by cell morphology and changes in cell surface antigen expression. For morphological analysis cytospin slides were stained with May-Grü nwald Giemsa and analyzed by light microscopy.
Analysis of cell surface antigens was performed by flow cytometry using a FACScan Flow cytometer (Becton DickinLeukemia son, Bedford, MA, USA). The following antibodies to membrane antigens were used: anti-CD11a, anti-CD11b, antiCD11c, anti-CD14, anti-CD15, anti-CD33, anti-CD34, anti-CD38 and anti-CD54 directly conjugated with fluorochromes. Cells were labeled with these antibodies as previously reported. 29 Briefly, the cells were incubated for 30 min at 4°C with an appropriate dilution of antibody and after three washings in PBS the cells were fixed in PBS formaldehyde (4%) and analyzed by flow cytometry. The results were expressed in terms of the percentage of positive cells and of the mean fluorescence intensity (MFI). The cutoff of MFI to distinguish between negative and positive cells corresponds to a value of 10 for CD11a, CD11b, CD11c, CD18 and CD54 and of 5 for CD15 and CD38.
Functional differentiation to a mature myelomonocytic phenotype capable of inducible oxidative metabolism was assayed by phorbol-12-myristate-13-acetate (TPA; Sigma) inducible intracellular reduction of nitroblue tetrazolium to formazan. Cells (0.1 × 10 6 ) were harvested at the indicated times and resuspended in 0.2 ml of 2 mg/ml nitroblue tetrazolium in PBS containing 100 ng/ml PMA. The cells were incubated in a water bath for 20 min at 37°C and then scored using a hemocytometer for the percentage of cells containing intracellular superoxide precipitated formazan.
Hematopoietic growth factor receptor (HGFR) expression
30 was purchased from Pharmingen (San Diego, CA, USA); PE-labeled anti-c-kit and anti-GM-CSFR ␣ chain mAbs were obtained from Immunotech (Immunotech, Marseille, France); purified anti-cfms, clone 3-4A4 30 was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Cells were incubated with optimal concentrations of these mAbs and processed for flow cytometry analysis as above.
For M-CSFR (c-fms) expression the cells were incubated for 30 min at 4°C in the presence of anti-c-fms mAb; after washing three times in PBS containing 2 mg/ml bovine serum albumin (BSA) the cells were incubated with a 1:50 dilution of FITC-labeled affinity-purified rabbit anti-rat immunoglobulins. After three additional washings, the cells were analyzed by flow cytometry.
For G-CSFR analysis, cells were incubated for 60 min, at 4°C with PE-labeled G-CSF (R&D Systems, Minneapolis, MN, USA), washed and then analyzed by flow cytometry.
All controls necessary to verify the specificity of each of these reagents are reported in Ref 26 . Appropriate negative controls were also used for each of these reagents, as reported in Ref. 26 .
The results were expressed in terms of the percentage of fluorescent cells and of the mean fluorescence intensity (MFI). MFI was expressed as the ratio between the fluorescence intensity observed in cells labeled with anti-c-fms and in cells labeled with a negative control antibody.
Cell sorting
Leukemic blasts stained with an anti-c-fms antibody were sorted according to fluorescence intensity into c-fms dim and cfms bright fractions using a FACS Vantage (Becton Dickinson). ND, not determined.
Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of c-fms mRNA
Total RNA was extracted by the guanidinium isothiocyanate/Cl method 31 and normalized by dot hybridization with a human rRNA probe. 32 The normalized RNA was reverse transcribed according to the manufacturer's instructions (GIBCO-BRL, Gaithersburg, MD, USA). The RT-PCR was normalized for ␤2-microglobulin 32 (amplification within the linear range was achieved by 20 PCR cycles: denaturation at 95°C for 30 s, annealing at 54°C for 30 s, and extension at 72°C for 45 s). To evaluate the expression of c-fms mRNA, an aliquot of RT-RNA (corresponding to~2 ng RNA) was amplified within the linear range by 30 PCR cycles. Each sample was electrophoresed in 2% agarose, transferred on to nylon membrane, and hybridized with a specific c-fms probe. Positive controls (normal human monocytes) were normalized for ␤2-microglobulin and included in all PCR assays. For negative controls, an aliquot of RNA (~2 ng) from each sample was amplified to exclude the presence of contaminant DNA; a mock reaction was also included.
The following primers and probe were used for c-fms detection: primer 5Ј:AGAGCATCTTCGACTGTG (3946-3964); Primer 3Ј: GAACTTGGCTGTTCACCAG (4051-4068); probe: ACGTCTGGTCCTATGGCATCTTGCTCTGG (3984-4012). Annealing temperature was at 50°C.
Preparation of whole cell extracts
) were washed twice in cold phosphate-buffered saline and then collected by centrifugation. The pellet was resuspended in 300 l of lysis buffer containing 20 mM Hepes, 50 mM NaCl, 10 mM EDTA, 2 mM EGTA, and 0.5% (vol/vol) Nonidet P-40 (pH 8) supplemented with 0.5 mM dithiothreitol, 10 mM sodium molybdate, 10 mM sodium orthovanadate, 100 mM NaF, 10 g of leupeptin per ml, and 0.5 mM phenylmethylsulfonyl fluoride (PMSF). After incubation for 30 min on ice, the suspension was centrifuged at 10 000 g for 10 min. The supernatants were aliquoted and stored at −80°C. The protein concentration in the soluble supernatant was determined using the Bio-Rad protein assay (Bio-Rad, Richmond, VA, USA).
EMSA (electrophoretic mobility shift assay)
Identification and characterization of PU.1 binding to the M-CSF receptor promoter was assessed by gel mobility shift using a double-stranded M-CSF receptor promoter oligonucleotide extending from −61 to −22 bp and corresponding to the sequence 5Ј-TGCCTAGCTAAAAGGGGAAGAAGAGGATCA GCCCAAGGAG-3Ј. The binding-reaction mixture (20 l final volume) contained labeled oligonucleotide probes (10 000 c.p.m.) in binding buffer (75 mM KCI, 20 mM Tris-HCl (pH 7.5), 1 mM dithiothreitol) containing 5 g of bovine serum albumin per ml, 14% (vol/vol) glycerol, and 3 g of poly(dIdC). Total cell lysates (10 g) were added, and the reaction mixture was incubated for 20 min at room temperature. Samples were electrophoresed in a 5% poly-acrylamide gel in 0.5× Tris-borate-EDTA (TBE) buffer for 2 h at 200 V at 18°C. The gels were then dried and subjected to autoradiography. Competition studies were performed by adding unlabeled double-stranded oligonucleotides at a 100-fold molar excess over the labeled probe. The following DNA oligonucleotide Leukemia sequences were used: (1) wt PU.1 box: 5Ј-TGCCTAGCTAAAA GGGGAAGAAGAGGATCAGCCCAAGGAG-3Ј; (2) mutant PU.1 box: 5Ј-TGCCTAGCTAAAAGGGATCGTAGCGGATCA GCCCAA-GGAG-3Ј.
Western blotting
Western blot analysis was performed with rabbit anti-human PU.1 Ab (Santa Cruz Biotechnology) or rat anti-human c-fms, clone AFS-10-6-1 (BD Pharmingen) by enhanced chemiluminescence, according to the manufacturer's protocol (Amersham, Little Chalfont, UK).
Statistical analysis
The statistical analysis between sets of data was performed using the two tailed t-test for paired values.
Plasmid construction and cell transfection
NB4 cells were transfected using the pc-fms/REP4 vector, a plasmid bearing c-fms in an episomal expression vector. The pREP4 (Invitrogen) was an episomally replicating vector containing an EBNA enhancer and EBV origin of replication. The c-fms c-DNA used was originally derived from a DNA fms minigene containing 5.3 kb flanking genomic sequence attached to the fms c-DNA (kindly provided by Dr Tom Look, Department of Medicine, Beth Israel Hospital, Boston, MA, USA) and subsequently modified. The EcoRI/BamHI fragment from the cDNA, was blunted in the EcoRI site, ligated following Klenow fill-in and cloned into the corresponding BamHI/PvII site of the multiple cloning site of the episomal pREP4 vector.
c-fms c-DNA protein was controlled by tnt lysate coupled transcription/translation systems (Promega, Madison, WI, USA) according to the manifacturer's protocols. Wild-type NB4 cells (10 × 10 6 cells in 0.5 ml RPMI-1640) were electroporated (Bio-Rad Gene Pulser, settings: capacitance 500 F, voltage 300 V) with 20 g of supercoiled plasmid DNA. Cells and plasmid were incubated for 5 min at RT prior to electroporation. The cuvettes were transferred to an ice bath for 15 min. immediately after transfection. The cells were than transferred to 10 ml of RPMI-1640 containing 10% fetal calf serum and 2 mM L-glutamine at 37°C. Approximately 20-30% of the cells survived. The electroporation procedure selection began at 60 h using medium containing 65 g/ml hygromycin B for 2 weeks, 80 g/ml for 3 days, and than 100 g/ml thereafter. Cells were maintained under constant selection pressure as described above.
FISH analysis
Cytospin samples were stained with May-Grü nwald Giemsa and cell pictures visualized on a photomicroscope (Olympus AX70 Provis) equipped with a SPOT-2 cooled CCD color digital camera (Diagnostic Instruments Inc) and a Delta System package software (IAS 2000 and FISH 2000) to acquire and edit images.
The slides were destained with 100% methanol and 100% ethanol, each for 3 min prior to in situ hybridization. The slides were then immersed in 2× SSC for 5 min at RT and then washed in 1× PBS for 5 min at RT. After washing, the slides were placed for 10 min in a 10 mg/100 ml 00.1 N HCl solution in a 37°C waterbath and postfixed in a 1% acid-free formaldehyde/1× PBS/MgC 2 solution at RT for 10 min. Finally, they were washed twice in PBS and dehydrated through an ethanol series (70-90% ethanol; 3 min each).
Dual locus hybridization was performed by using a locusspecific identifier PML/RAR␣ dual-color translocation probe (Vysis, Woodcreek, USA) as previously described 33 and according to the manufacturer's instructions.
In normal cells the pattern for a nucleus hybridized with the LSI PML/RAR␣ probe was a two orange and two green signal pattern. In an abnormal cell containing a PML/RAR␣ fusion, a one green (RAR␣), one orange (PML) and closely adjacent or fused green/orange (yellow) signal pattern was observed.
Figure 2
Flow cytometric analysis of c-fms expression in APL blasts (patient 6) grown for 1 or 2 weeks in the absence or presence of ATRA. The values of c-fms mean fluorescence intensity observed at day 0 are significantly different from those observed at day 7 (P = 0.001) and at day 14 (P = 0.002) of culture, while this difference is not significant between day 7 and day 14 (P = 0.165). Table 3 Immunophenotypic analysis of APL blasts derived from patient 10 (ATRA-resistant case) % Positive cells CD11a CD11b CD11c CD14  CD38  CD54  CD15  c-fms  Granulocytes  Monocytes   Control  12  5  32  0  84  5  63  32  0  0  ATRA  15  7  30  0  75  22  85  21  3  0  ATRA+IL-3+GM+G+M  28  24  43  5  100  37  100  45  29  5 APL blasts derived from patient 10 were analyzed either immediately after their isolation or after 7 days of in vitro growth in the presence of ATRA or ATRA+IL-3+GM+G-CSF and M-CSF
Figure 3
Morphological features of APL blasts derived from patient 1 and grown for different periods of time in the presence of ATRA. 1  0  68  94  0  32  6  0  61  88  2  0  14  37  0  86  63  0  7  29  3  0  6  23  0  94  77  0  5  18  4  0  5  10  0  95  90  0  5  9  5  0  15  20  0  85  80  0  35  40  6  0  6  19  0  94  81  0  5  16  7  0  7  16  0  93  84  0  7  12  8  0  1  2  0  9 9  9 8  0  3  2  9  0  1  2  0  9 9  9 8  0  3  2  11  0  22  23  0  78  77  0  37  27  12  0  10  12  0  90  88  0  35  21  13  0  11  15  0  89  85  0  13  18  14  0  8  11  0  92  89  0  11  14  17  0  4  12  0  96  88  0  2  4 A significant correlation between the number of monocytes and CD14 + cells was observed both at day 7 (r = 0.71, P = 0.001) and day 14 (r = 0.89, P = <0.0001) of culture.
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Results
Patients
We have investigated c-fms expression in 17 APL patients. Leukemic blasts from these patients were obtained at diagnosis and before the start of therapy for patients 1 to 9, 11 to 17 and at the time of relapse for patient 10. The main clinical and biologic features of these patients are reported in Table  1 . Patients 1 to 15 and 17 all displayed cytogenetic evidence of the 15;17 chromosomal translocation and showed PML/RAR rearrangement using a specific RT-PCR assay. Based on the latter, eight patients were classified as BCR1 and seven as BCR3. Patient 16 exhibited cytogenetic evidence of 11;17 chromosomal translocation by FISH and PLZF/RAR␣ rearrangement using a specific RT-PCR assay.
The immunophenotypic features of PML/RAR-␣ + patients are reported in Table 1 . Leukemic blasts were usually CD34 − (with the exception of patients 7 and 15); CD38 − (except for patients 9, 10, 12 and 15) and CD15
− (except for patients 10 and 14), displayed a variable positivity for CD11a, CD11b and CD11c and were constantly CD33 + . The PLZF/RAR␣ + patient showed an immunophenotype comparable to that displayed by PML/RAR-␣ + patients, with the exception of a lower CD33 positivity, moreover, blasts from this patient also stained positive for CD56 (not shown). All patients, with the exception of patients 3 and 15, were HLA-DR − . Furthermore, analysis of the main hematopoietic growth factors involved in the regulation of myeloid cell growth (IL-3R␣ chain, GM-CSFR␣ chain and IL-3R/GM-CSFR common ␤ chain, G-CSFR and c-fms) showed that all four receptors were expressed on the PML/RAR-␣ + APL blasts of all 15 cases (patients 1 to 9, 11 to 15 and 17) analyzed at the first clinical presentation of the disease, while the relapsing patient (patient 10) showed only a low expression of G-CSFR, c-fms, GM-CSFR␣ and IL-3R/GM-CSFR ␤ chain on leukemic blasts (Table  1) . Finally, the PLZF/RAR-␣ + patient showed low expression of IL-3R␣ and c-fms (Table 1) .
c-fms expression in APL
The constant expression of c-fms observed in all PML/RAR-␣ + APL cases is surprising if compared with the pattern observed in normal promyelocytes which express IL-3R␣, GM-CSFR␣ and G-CSFR, but not c-fms, whose expression is restricted at the level of the precursor compartment to the monocytic lineage. 26 We thus explored the pattern of c-fms expression in APL cells. Flow cytometric analysis of c-fms expression in APL blasts showed that all cases displayed >65% c-fms + cells, with the exception of patient 10 with relapsing M3 leukemia who exhibited only a low level of c-fms expression (Table 1) .
RT-PCR analysis of c-fms mRNA in 11 APL cases showed a constant positivity: 10 of the 11 cases displayed c-fms mRNA level comparable to that observed in circulating monocytes ( Figure 1) . We also evaluated the expression of c-fms after in vitro ATRA induction of APL blast differentiation. Cells grown in the presence of ATRA for 1 or 2 weeks displayed a significant increase in the level of c-fms expression, as supported by flow cytometry analysis (mean fluorescence intensity values) ( Figure 2 and Table 2 ). APL cells from patient 10 did not display a significant increase in the level of c-fms expression following in vitro incubation with ATRA (Table 3 ).
The blasts of this patient were resistant both in vitro and in vivo to the differentiative action of ATRA (Table 3) .
Granulocytic and monocytic differentiation of APL blasts
Since ATRA induced a significant increase in the level of cfms expression we evaluated whether this chemical inducer allows the maturation of APL cells not only to the granulocytic, but also to the monocytic lineage. This analysis was based both on morphological and immunophenotypical criteria. As reported above, in all but one patient, the majority of APL blasts displayed a typical granulocytic morphology after in vitro ATRA treatment. A variable proportion of APL blasts treated in vitro for either 7 or 14 days with ATRA exhibited a typical monocytic cell morphology: the proportion of monocytic cells was high in patient 1 (Figure 3) , while the other patients (patients 2 to 17) displayed a variable percentage of monocytic cells: between 1 and 15% at day 7 of culture, 2 and 37% at day 14 of culture; finally, patient 8 showed only a very low percentage (1-2%) of monocytes (Table 4) .
In parallel, we evaluated the percentage of cells displaying the CD14 antigen, a reliable marker of monocytic differentiation, on their membrane. There was a positive correlation between the percentage of cells recognized as monocytes according to morphologic criteria and the percentage of CD14
+ cells both at day 7 (r = 0.77, P < 0.01) and day 14 (r = 0.84, P < 0.01) ( Table 4) .
We then evaluated whether hematopoietic growth factors Table 5 ). Furthermore, cells grown in the presence of ATRA+IL-3+GM-CSF+M-CSF displayed a higher level of myeloid differentiation marker expression (CD11a, CD11b, CD11c, CD14 and CD54), than cells grown with ATRA alone ( Figure 5 and Table 5 ); particularly the percentage of CD11a (P = 0.011), CD11b (P = 0.014) and CD14-positive cells (P = 0.02) and of monocytes (P = 0.009) was significantly higher in
Figure 5
Flow cytometry analysis of c-fms and CD14 expression on leukemic blasts derived from patient 7 and grown for 1 week either in the absence (control) or presence of ATRA alone or combined with IL-3, GM-CSF and M-CSF.
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ATRA+IL-3+GM-CSF+M-CSF-treated cells than in cells grown
with ATRA alone (one example of the morphological features of these cells is shown in Figure 6b ). These findings indicate that cells grown in the presence of both ATRA and HGFs undergo terminal maturation.
Analysis of cell growth showed that APL cells grown in the presence of ATRA exhibited an initial (from day 0 to day 2) slight decrease of their cell number, followed by a slight increase of their cell number from day 2 to day 7. From day 7 to day 14 of culture a slight decrease of the cell number was observed. APL cells grown in the presence of ATRA+GFs do not show the initial decline in their cell number, but remained stationary and then undergo proliferation at a moderate rate from day 2 to day 9; at late days of culture (ie from day 9 to day 14) a slight decrease of the cell number was observed (Figure 6c ). The proportion of apoptotic cells was at all the different days of culture only slightly lower in cells grown with ATRA+GFs as compared to that observed in cells grown with ATRA alone (Figure 6c ). Table 1 ) according to the level of cfms expression (bottom panels). c-fms + and c-fms +++ fractions, as well as the total leukemic cell population, were grown in vitro in the presence of ATRA and analyzed for membrane antigen expression and for morphological detection of monocytic cells (top panels). In the bottom panel the x axis represents the fluorescence intensity, while the y axis indicates the number of events.
Interestingly, the addition of ATRA+GFs to the cells of the patient resistant to ATRA elicited a partial differentiation, while ATRA alone was ineffective (Table 3) .
In parallel, evaluation of c-fms expression in APL cells induced either with ATRA or ATRA+HGFs (ie IL-3+GM+M-CSF) showed a marked increase of M-CSFR expression in both culture conditions, as compared with uninduced cells: however, APL cells grown in the presence of ATRA+HGFs (ie IL-3+GM+M-CSF) displayed a c-fms fluorescence intensity lower than cells grown with ATRA alone (Figure 5 ). This phenom-
Figure 6
Continued.
enon is seemingly due to a possible downmodulation of c-fms expression by exogenous M-CSF.
APL cells expressing elevated levels of c-fms exhibit monocytic differentiation capacities
To evaluate whether the level of c-fms expression in APL blasts represents a marker underlying the monocytic differentiation capacities of these cells, we labeled APL cells with anti-c-fms mAb and then sorted them according to fluorescence intensity into c-fms dim and c-fms bright fractions: the latLeukemia ter one prevailingly exhibited the capacity to generate monocytic cells following in vitro incubation with ATRA ( Figure 6d ).
Monocytic cells present in ATRA-differentiated APL cells pertain to the leukemic clone
To evaluate whether monocytes in vitro originated from the differentiation of blasts pertain to the leukemic clone, FISH analysis specific for the detection of the 15;17 chromosomal translocation was performed. This analysis provided evidence that the majority of in vitro differentiated cells with morpho- logical features of granulocytes and monocytes bear the 15;17 translocation ( Figure 7 ). This observation is also reinforced by the morphological findings observed for patient 1 (see Figure  3 ) whose blasts following ATRA induction exhibited a predominant monocytic morphology: a significant proportion of these cells displayed in their cytoplasm Auer bodies, a peculiar feature of leukemic cells.
Analysis of PU.1 binding to the c-fms promoter
Previous studies have shown that a PU.1 site located in the c-fms promoter plays a key role in the expression of this gene, as supported both by deletional and mutational analyses of the c-fms promoter and PU.1 gene knockout studies. 34, 35 Both extracts derived from control and ATRA-induced APL cells showed a single PU.1 binding activity to M-CSF receptor promoter (Figure 8a) . Interestingly, the level of binding activity was higher in ATRA-treated than in control APL cells ( Figure  8a ). The PU.1 specificity of the nuclear factors which bind the PU.1 box of the c-fms promoter was directly supported by competition experiments. Competition with excess homologous oligonucleotide abolished the formation of the complex, while competition with the oligonucleotide containing point mutations in the PU.1 site did not affect complex formation (Figure 8a) . Furthermore, preincubation of cell extracts with anti-PU.1 Ab completely abolished the PU.1 box binding complex (Figure 8a ).
Western blot analysis was performed to evaluate PU.1 protein levels in APL cells, before and after induction in vitro with ATRA (Figure 8b) . In all whole cell extracts the predominant protein detected by the anti-PU.1 antiserum migrated with an apparent molecular weight of about 28 kDa. Interestingly, PU.1 protein levels were higher in ATRA-induced than in control APL cells.
In this context, the observation that the rise of PU.1 is more pronounced in patients exhibiting monocytic differentiation following ATRA induction (patients 7 and 11) than in patients who did not undergo monocytic maturation (patients 8 and 9) (Figure 8a and b) is particularly interesting.
Enforced c-fms expression in NB4 favors monocytic differentiation
To evaluate whether c-fms expression could play a role in the capacity of APL cells to undergo monocytic differentiation, we induced the enforced expression of c-fms in NB4, a promyelocytic cell line derived from a PML/RAR␣ + APL patient. It is of interest to note that uninduced NB4 cells were completely negative for CD11b and CD14 expression, while only a minority of them (about 10%) exhibits reactivity with anti-CD11c and CD11a mAbs ( Table 6 ). The observations concerning the expression of CD11b and CD11c are at variance with other recent reports, where a low reactivity of NB4 cells was observed with anti-CD11b but not with anti-CD11c. 34, 35 These differences may be tentatively ascribed to a heterogeneity occurring during in vitro passages. However, in spite of these differences our NB4 cells display capacities of differentiation and levels of PML/RAR␣ expression identical to those previously reported. 34, 35 Analysis of c-fms protein expression by Western blotting showed a sustained level of this protein constitutively expressed in cells transduced with the c-fms gene, but not in cells transduced with the empty pREP vector (Figure 9 ). The analysis of the differentiation properties of these cells showed several interesting findings: (1) NB4 cells overexpressing c-fms displayed an increased capacity of monocytic maturation as compared to the control cells transduced with the empty pREP vector only when they were grown in the presence of M-CSF; (2) the greatest monocytic differentiation potential was displayed only when NB4 c-fms are grown in the presence of 1␣250H-VitD3, M-CSF and a protein kinase C activator (TPA), while a few percentage of cells displayed the monocytic maturation antigen CD14 when they were grown in the presence of either ATRA or 1␣250H-VitD3; (3) NB4 c-fms cells exhibited an increased inducibility of mem- brane maturation markers, such as CD11a, CD11b, CD11c and CD54, over NB4 pREP cells when grown in the presence of M-CSF combined either with ATRA, 1␣250H-VitD3 or 1␣250H-VitD3 and TPA (Table 6) .
Discussion
Few studies have attempted to characterize the expression of HGFs and their receptors in APL. The majority of APL cases were found to express IL-1␣, IL-6 and TNF-␣, but not G-CSF, GM-CSF and IL-3, while a minority of patients showed a similar HGF expression pattern 36, 37 but did not synthesize TNF-␣. 38, 39 Furthermore, APL blasts possess GM-CSFRs, whose expression is potentiated following ATRA treatment. 40 c-fms expression is observed in 15% 41 to 50% 42, 43 of AML cases, Leukemia particularly in the M5 subset. 42 Only two M3 patients were analyzed, and both were shown to be c-fms + . 42, 43 In this study we show that PML/RAR␣ + blasts from 15 APL patients consistently expressed c-fms, whose level was enhanced after ATRA treatment. While M-CSF alone or with ATRA did not stimulate proliferation or survival of APL cells, combined addition of M-CSF, other myeloid GFs (IL-3, GM-CSF and G-CSF) and ATRA potentiated monocytic maturation of APL cells, ie elicited a significant increase in the proportion of cellular elements differentiating along the monocytic lineage, as shown by immunophenotypical and morphologial criteria. This potentiation of monocytic differentiation was not observed when the myeloid GFs (IL-3, GM-CSF and G-CSF) and ATRA were added in the absence of M-CSF, thus implying that activation of c-fms is required for this phenomenon.
In line with these observations previous studies on the pro- myelocytic leukemia NB4 cells have provided evidence that these cells are capable of both granulocytic and monocytic differentiation. 24, 45 Interestingly, also in these studies the presence of M-CSF was required to induce monocytic maturation of NB4 cells. 24, 25 The capacity of APL cells to exhibit monocytic maturation capacities, in addition to the well known neutrophilic differentiation capacity, is an intrinsic property of the leukemic clone and is not due to the differentiation of normal hemopoietic cells. This conclusion was directly supported by two sets of observations: (1) the majority of neutrophilic as well as of monocytic cells derived from the in vitro maturation of APL blasts displays the 15;17 translocation as shown by the FISH technique; (2) many monocytic cells originated from APL blasts incubated with ATRA display Auer bodies, a peculiar abnormality of leukemic cells.
c-fms expression on APL cells is a key marker for their monocytic differentiation capacity. In fact, fractionation of APL cells according to the level of c-fms expression showed that the monocytic potential of APL cells is prevailingly displayed by the leukemic population expressing the highest levels of cfms. This finding indicates that c-fms represents a marker of the monocytic potential of APL blasts and its level of expression on leukemic cells directly correlates with their capacity for monocytic maturation.
These results indicate that APL blasts are responsive to both 111  Table 6 Immunophenotype analysis of NB4 cells transduced either with the empty PREP vector or with the c-fms containing vector and grown for 4 days in the conditions reported below %, percentage of positive cells; MFI, mean fluorescence intensity. *P = < 0.05; **P < 0.01;***P = < 0.001. the proliferative and differentiative stimuli exerted by HGFs. Furthermore, these observations suggest that APL blasts, although morphologically resembling promyelocytes, functionally mimic normal CFU-GM, in view of their capacity to differentiate along both granulocytic and monocytic lineages.
It is of interest to note that recent studies [44] [45] [46] have provided evidence that APL blasts also possess the capacity to differentiate to functional dendritic cells. This finding is fully compatible with our observations and it is tempting to suggest that the APL blasts differentiating to dendritic cells under appropriate culture conditions (ie in the presence of GM-CSF, IL-4 and Leukemia TNF-␣), represent the same population able to mature to monocytic cells also under the culture conditions here reported. This hypothesis is supported by the strict link existing between the monocytic and dendritic cell lineages. 47 Experiments of enforced c-fms expression into the promyelocytic PML/RAR-␣ + NB4 cell line provided evidence that cfms could be mechanistically involved in the monocytic differentiation capacity of APL blasts. In fact, in the presence of M-CSF and inducers of myeloid differentiation (such as ATRA, 1␣250H-VitD3 or TPA) c-fms NB4 cells undergo monocytic maturation at a level significantly higher than that observed in control NB4 cells.
Interestingly, blasts from a patient with ATRA-resistant relapse displayed low c-fms expression as also observed on leukemic blasts derived from a patient with PLZF/RAR-␣ + APL: this observation suggests that consistent c-fms expression correlates with sensitivity to ATRA-sensitive PML/RAR-␣ + APLs. During the process of normal hematopoietic differentiation c-fms expression is virtually absent in quiescent hematopoietic progenitors and is then initially induced by HGFs triggering cell proliferation; 24 at a later differentiation stage, c-fms expression is restricted to cells pertaining to the monocytic lineage, while it is very low or absent in other lineages, including the granulocytic one. 26 Particularly, normal promyelocytes do not express c-fms. 26 According to these observations, the expression of c-fms on leukemic promyelocytes is apparently related to the leukemic process and their bipotential differentiation capacity.
While previous studies rarely reported the expression of the M-CSFR in APL, indirect evidence suggested a possible role of this receptor in APL. Thus, combined therapy with M-CSF and chemotherapy was successful in two cases of chemotherapy-resistant APL. 48 In HL-60 cells c-fms overexpression of transduced c-fms gene resulted in an increased sensitivity to ATRA, as evaluated in terms of growth inhibition and differentiation capacity. 49 Finally, ATRA markedly stimulates M-CSF and GM-CSF production by normal human bone marrow stromal cells; 50 increased production of these cytokines may play an important role in vivo in the induction of APL cell differentiation. 50 The molecular mechanisms responsible for c-fms expression in APL cells remain largely unknown. However, the constitutive PU.1 expression in APL cells may, at least in part, contribute to the expression of this receptor. In fact, pre-vious studies provided evidence on the key role of this transcription factor in the control of M-CSFR expression in monocytic cells. 36, 37, 51 In this context the observation that PU.1 null cells had no detectable M-CSF receptors is particularly relevant. 49 Furthermore, in APL cells ATRA upmodulates both cfms and PU.1 expression, further suggesting the existence of a functional link in APL cells between PU.1 and c-fms expression. In this context it was particularly interesting that the rise in PU.1 levels was clearly more pronounced in patients exhibiting a clear monocytic maturation following ATRA induction as compared to that observed in patients who did not undergo monocytic maturation after ATRA treatment.
In addition to c-fms, we observed the presence of CCR5 in APL cells, the receptor for MIP-1␣, MIP-␤ and RANTES, whose expression is restricted in normal hematopoietic cells at the level of the monocytic lineage. 52 In fact, preliminary observations on five APL patients showed CCR5 expression in the majority of uninduced and ATRA-induced APL cells (data not shown).
In addition to M-CSFR expression, APL cells constantly and constitutively express IL-3R, GM-CSFR, and G-CSFR, and are particularly responsive to corresponding HGFs in terms of cell proliferation and protection from apoptosis (data not shown). Furthermore, the combined addition of IL-3, GM-CSF and M-CSF or IL-3, GM-CSF and G-CSF with ATRA markedly enhanced the level of cell maturation, as compared to that induced by ATRA alone; particularly the first cocktail comprising M-CSF potentiated the monocytic differentiation of APL cells by both morphologic and immunophenotypic criteria. The combined administration of ATRA+HGFs may have implications for the treatment of APL. In this context, case report studies performed on relapsed APL patients have shown that the combined treatment with ATRA+G-CSF was apparently capable of inducing complete remission. 53 Furthermore, the administration of G-CSF during the induction therapy with ATRA of APL patients accelerates the recovery of the hematological condition and, in some cases, the disappearance of leukemic blasts. 54 Finally, a recent report showed complete remission of t(11;17)-positive acute promyelocytic leukemia induced by combined RA and G-CSF administration. 55 In conclusion, the present study provides evidence that PML/RAR-␣ + APL blasts are in many aspects comparable to CFU-GM, particularly in their capacity to differentiate along both granulocytic and monocytic lineages; furthermore, monocytic differentiation is linked to the extent of c-fms expression.
